Needham Reiterates Buy on OncoCyte, Maintains $4.25 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Mike Matson has reiterated a Buy rating on OncoCyte (NASDAQ:OCX) and maintained a price target of $4.25.
October 15, 2024 | 9:41 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Mike Matson has reiterated a Buy rating on OncoCyte (NASDAQ:OCX) and maintained a price target of $4.25, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $4.25 price target by Needham suggests a positive outlook for OncoCyte. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100